News FDA approves consumer colorectal cancer test The FDA will allow consumer DNA testing company 23andMe to give customers reports on their risk of hereditary colorectal cancer.
R&D GSK signs $300m R&D deal with 23andMe GlaxoSmithKline signed a $300 million research and development deal with mail gene profiling company 23andMe, gaining access to four million customers DNA information.
News Direct-to-consumer DNA and microbiome test launched in Europ... A UK-based company offering DNA and microbiome tests directly to consumers has expanded its services to 10 more European countries.
News FDA to streamline access to consumer genetic tests New regulations require less pre-market data for approval.
News Fulcrum Therapeutics promises new drugs for rare disorders Company launched following $55 million series A funding round.
News Strata Oncology secures funding for free tumour profiling pr... Strata Oncology secures financing to advance its free tumour sequencing in US.
News Just how radical is the FDA's complete response letter move? The FDA says publishing complete response letters for medicines is an act of "radical transparency," but it is not as revolutionary as it seems.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face